荣昌生物将处于临床阶段的PD-1/VEGF双特异性抗体RC148授权给艾伯维，交易总金额56亿美元（含首付6.5亿美元）；宜联生物将B7H3 ADC授权罗氏，获得5.7亿美元首付款及近期里程碑付款；海思科PDE3/4双重抑制剂与美国AirNexis Therapeutics公司合作，获得1.08亿美元首付款，总额超10亿美元。这些大额交易的密集落地，构成了2026年开年BD行情的坚实基础。
2025-09-08 15:30:53 +02:00
。关于这个话题，新收录的资料提供了深入分析
Anthropic's Claude overtakes ChatGPT in App Store。新收录的资料对此有专业解读
▲ 图源：Android Central，详情可参考新收录的资料
In using such terms, Tesla has misled drivers and poses a consumer risk, the decision said. Tesla has faced multiple legal challenges that its self-driving features led to the deaths of multiple people. The company was found partially liable for a fatal, autopilot-related incident in August.